The Phase III FIND-CKD trial reported that finerenone slowed kidney function decline and reduced cardiovascular risk in adults with chronic kidney disease without diabetes. The company characterized the study as the largest of its kind and presented outcomes tied to decelerating renal progression in non-diabetic CKD populations. While detailed endpoint numbers were not provided in the available summary, the trial’s framing suggests finerenone’s benefits may extend beyond diabetic CKD where it is already established, with potential implications for guideline positioning in broader CKD subgroups. The results land as competing CKD approaches continue to emphasize cardiorenal risk reduction, and as mineralocorticoid receptor antagonism remains a core immuno-inflammatory and fibrotic pathway target. If the full dataset supports the reported direction of benefit, it could prompt additional development and label conversations across CKD phenotypes.